Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Shanghai Pharmaceuticals Holding Co. Ltd. manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 4 pending office actions, each assigned to a different person among 4 distinct examiners. This distribution suggests a diverse range of inquiries across the company's active applications.
The workload is spread across 4 distinct art units, indicating that the pending matters involve varied technical sub-specialties within the biotechnology and pharmaceutical fields. IVANOVA, SVETLANA M is listed as the busiest examiner, although she is responsible for 1 pending office action. This means that no single examiner or art unit dominates the current prosecution landscape.
Practitioners must manage separate relationships across the 4 distinct art units to advance this portfolio. Since each of the pending office actions is with a different examiner, the company faces multiple independent sets of examination hurdles. This diversity reduces the risk that a single examiner's tendencies will negatively impact the entire portfolio of pending Biotechnology & Pharmaceuticals matters.
The busiest examiner pending count of 1 shows an even distribution of work among the 4 distinct examiners. Reviewing the history of each examiner within the Biotechnology & Pharmaceuticals space can help anticipate potential hurdles. Monitoring the status of all 4 pending office actions is vital for timely adjustments to the broader intellectual property strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IVANOVA, SVETLANA M | 1 | 50.9% | +51.5% |
| STOCKTON, LAURA LYNNE | 1 | 75.2% | +33.7% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
| CORNET, JEAN P | 1 | 42.1% | +47.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18284162 | APPLICATION OF COMPOUND IN PREPARATION OF INHIBITORY DRUG TARGETING ERBB2 MUTANT | STOCKTON, LAURA LYNNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18024807 | APPLICATION OF NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | CORNET, JEAN P | 56d |
| 18606090 | METHOD FOR TREATING OR PREVENTING A DISEASE OF INCOMPLETE IMMUNE RECONSTITUTION IN AIDS USING (5R)-5-HYDROXYTRIPTOLIDE | IVANOVA, SVETLANA M | — |
| 18284162 | APPLICATION OF COMPOUND IN PREPARATION OF INHIBITORY DRUG TARGETING ERBB2 MUTANT | STOCKTON, LAURA LYNNE | — |
| 18276569 | SALT OF NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND OR CRYSTAL FORM THEREOF, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | RZECZYCKI, PHILLIP MATTHEW | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1626 | 1 |
| 1625 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18606090 | METHOD FOR TREATING OR PREVENTING A DISEASE OF INCOMPLETE IMMUNE RECONSTITUTION IN AIDS USING (5R)-5-HYDROXYTRIPTOLIDE | IVANOVA, SVETLANA M | 1627 | §103 | Final Rejection | — | Pending | Mar 15, 2024 |
| 18284162 | APPLICATION OF COMPOUND IN PREPARATION OF INHIBITORY DRUG TARGETING ERBB2 MUTANT | STOCKTON, LAURA LYNNE | 1626 | §102§112Other | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18276569 | SALT OF NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND OR CRYSTAL FORM THEREOF, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | RZECZYCKI, PHILLIP MATTHEW | 1625 | §112 | Non-Final OA | — | Pending | Aug 09, 2023 |
| 18024807 | APPLICATION OF NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | CORNET, JEAN P | 1628 | §103DPOther | Non-Final OA | 56d | Pending | Mar 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial